Clinical Trials
59 trialsA Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
BeOne Medicines
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
Atavistik Bio, Inc
TTBF
University of California, San Francisco
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
IDEAYA Biosciences
STARTRK-2
Hoffmann-La Roche
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
Alterome Therapeutics, Inc.
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
GlaxoSmithKline
OvAR-Y
Washington University School of Medicine
SURVIMON
N.N. Petrov National Medical Research Center of Oncology
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
MK-2870-001
Klus Pharma Inc.
HER-CROWN
Ottawa Heart Institute Research Corporation
Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
PF-07104091 as a Single Agent and in Combination Therapy
Pfizer
JCDATAZONEWH
The University of Hong Kong
GERSOM
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Evaluation of Improved Onboard Patient Imaging
Varian, a Siemens Healthineers Company
MEDIOLA
AstraZeneca
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
MOMA Therapeutics
ROSY-O
AstraZeneca
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients
Memorial Sloan Kettering Cancer Center
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer
Amgen
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability
Rutgers, The State University of New Jersey
Effectiveness and Impact of the Lived Experience Cancer Awareness Campaign on Screening Participation
International Agency for Research on Cancer
HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics
City of Hope Medical Center
Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members
M.D. Anderson Cancer Center
Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention
M.D. Anderson Cancer Center
ONE TEAM
Duke University
PETRA
AstraZeneca
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
Poseida Therapeutics, Inc.
SHE-WOMEN
University of Kansas Medical Center
Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer
University of Washington
Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers
Memorial Sloan Kettering Cancer Center
mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian
M.D. Anderson Cancer Center
Potlako+
Brigham and Women's Hospital
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
Seagen Inc.
C3Link
Implenomics
ESIGON
Assistance Publique - Hôpitaux de Paris
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
BicycleTx Limited
Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors
SystImmune Inc.
IMPACT
Vanderbilt-Ingram Cancer Center
Assessing the Time Demands of Cancer
Masonic Cancer Center, University of Minnesota
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Sensei Biotherapeutics, Inc.
Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues
Jonsson Comprehensive Cancer Center
Clinical Significance of Germline BRCA Mutations
Memorial Sloan Kettering Cancer Center
AMPLIFY
University of Alabama at Birmingham
Assessment of Paclitaxel-Induced Neuropathy
University of Chicago
EMBER
Eli Lilly and Company